Majority of Americans Support FDA Accessibility for Popular Peptides

Want the full story?
Read the complete article at KVIA
AI Summary
A recent survey by Hone Health reveals that 83% of U.S. adults familiar with peptides advocate for the FDA to allow licensed compounding pharmacies to produce seven specific peptides with a physician's prescription. The Pharmacy Compounding Advisory Committee (PCAC) will meet on July 23-24, 2026, to discuss adding these peptides to the 503A Bulks List, which would enable safer access for consumers currently relying on unregulated sources. Dr. Abid Husain emphasizes that regulated access could mitigate risks associated with gray-market peptides, which often contain harmful impurities. The decision from the FDA is expected by late 2026, with 39% of potential users indicating that reclassification would encourage them to try peptides.
Key Details: • FDA advisory committee meeting on July 23-24, 2026. • Survey conducted from May 8-11, 2026, with 2,491 participants. • Potential FDA decision on peptide accessibility expected by November or December 2026. • 9 in 10 respondents trust physician involvement in peptide prescriptions.